3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 1
2
Phase NA
1
Phase 4
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Gastrointestinal Stromal Tumors
2
Progressive Gastrointestinal Stromal Tumor
1
Myeloproliferative Disorders
1
Mastocytosis, Systemic
1
Mastocytosis
1
Mast Cell Activation Disorders
1
Leukemia, Myeloid, Chronic-Phase
1
Hematologic Neoplasms
1
Breast Neoplasms
1
Blast Crisis
1
Interventions
Letrozole
20
Docetaxel
16
Cyclophosphamide
13
Zoledronic Acid
12
exemestane
11
Trastuzumab
11
Anastrozole
11
Paclitaxel
10
Tamoxifen
9
Capecitabine
9
Fulvestrant
8
Epirubicin
8
pegfilgrastim
7
pertuzumab
6
liposomal doxorubicin
6
abemaciclib
6
Saline Solution
6
palbociclib
5
Sodium Chloride
5
Dexmedetomidine
5
Carboplatin
5
Bupivacaine
5
Bevacizumab
5
ribociclib
4
pegylated granulocyte colony-stimulating factor
4
eribulin
4
Tranexamic Acid
4
Standard of Care
4
Pamidronate
4
Filgrastim
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Breast Neoplasms
×
Imatinib Mesylate
×
Clear all
NCT00372476
2017-02-07
INV181
Novartis
Phase 4
Completed
33 enrolled